ArticleObesity (Silver Spring, Md.)2016
Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans.
Article in Obesity (Silver Spring, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 179 citations in OpenAlex.
- Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients.BMC psychiatry · 2024Trial
- Substitution of dietary monounsaturated fatty acids from olive oil for saturated fatty acids from lard increases low-density lipoprotein apolipoprotein B-100 fractional catabolic rate in subjects with dyslipidemia associated with insulin resistance: a randomized controlled trial.The American journal of clinical nutrition · 2024Trial
- n-3 PUFA and caloric restriction diet alters lipidomic profiles in obese men with metabolic syndrome: a preliminary open study.European journal of nutrition · 2020Trial
- Plasma lipid profiling of tissue-specific insulin resistance in human obesity.International journal of obesity (2005) · 2019Trial
- Trial
- Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle.JCI insight · 2018Trial
- Sphingolipid Metabolism in Obesity: Bidirectional Regulation and Comparative Perspectives on Plant Sphingolipids.Nutrients · 2026Review
- Ceramide metabolism in oxidative and glycolytic muscle: Significance for lipid-induced insulin resistance.Molecular metabolism · 2026Article
- Detergents without a drain: the evolutionary logic (and liability) of sphingolipids.Journal of lipid research · 2026Review
- Exercise triggers integrated lipid, sphingolipid and purine metabolic alterations in midlife women.Frontiers in physiology · 2026Article
- Pro‑inflammatory insulin‑resistant lipid phenotype in down syndrome identified byScientific reports · 2025Article
- Skeletal muscle insulin resistance in prediabetes: a lipidomic perspective on diacylglycerols, ceramides, and phospholipids.Scientific reports · 2025Article
- Integrative multi-omics analysis reveals molecular signatures of central obesity in children.Pediatric research · 2025Article
- Predictive Utility and Metabolomic Signatures of TG/HDL-C Ratio for Metabolic Syndrome Without Cardiovascular Disease and/or Diabetes in Qatari Adults.Metabolites · 2025Article
- Trans-omics analyses identify the biochemical network of LPCAT1 associated with coronary artery disease.Biomarker research · 2025Article
- Fecal Dysosmobacter spp. concentration is linked to plasma lipidome in insulin-resistant individuals with overweight, obesity and metabolic syndrome.Lipids in health and disease · 2025Article
- Abdominal obesity in youth: the associations of plasma Lysophophatidylcholine concentrations with insulin resistance.Pediatric research · 2025Article
- Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes.Journal of internal medicine · 2025Review
- Human skeletal muscle disuse atrophy has profound and negative effects on the muscle metabolome and lipidome.American journal of physiology. Endocrinology and metabolism · 2025Article
- Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlterations in lipids in muscle and plasma have been documented in insulin-resistant people with obesity. Whether these lipid alterations are a reflection of insulin resistance or obesity remains unclear.
methodsNondiabetic sedentary individuals not treated with lipid-lowering medications were studied (n = 51). Subjects with body mass index (BMI) > 25 kg/m(2) (n = 28) were stratified based on median glucose infusion rate during a hyperinsulinemic-euglycemic clamp into insulin-sensitive and insulin-resistant groups (above and below median, obesity/insulin-sensitive and obesity/insulin-resistant, respectively). Lean individuals (n = 23) served as a reference group. Lipidomics was performed in muscle and plasma by liquid chromatography electrospray ionization-tandem mass spectrometry. Pathway analysis of gene array in muscle was performed in a subset (n = 35).
resultsIn muscle, insulin resistance was characterized by higher levels of C18:0 sphingolipids, while in plasma, higher levels of diacylglycerol and cholesterol ester, and lower levels of lysophosphatidylcholine and lysoalkylphosphatidylcholine, indicated insulin resistance, irrespective of overweight/obesity. The sphingolipid metabolism gene pathway was upregulated in muscle in insulin resistance independent of obesity. An overweight/obesity lipidomic signature was only apparent in plasma, predominated by higher triacylglycerol and lower plasmalogen species.
conclusionsMuscle C18:0 sphingolipids may play a role in insulin resistance independent of excess adiposity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.